The Global Point of Care Infectious Disease Testing Market was valued at USD 2.635 Billion in 2023 and is projected to reach USD 5.137 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period (2023–2032). This growth is being driven by the rising prevalence of infectious diseases, increasing demand for rapid diagnostics in remote and underserved areas, and the accelerating adoption of mobile and self-testing devices across hospitals, clinics, and home settings.
As the healthcare industry shifts toward decentralized testing and immediate results to combat outbreaks effectively, the focus is on innovative diagnostic companies that are advancing point-of-care (POC) technologies for infectious diseases. These leaders are enhancing accuracy, speed, and accessibility, from HIV and influenza to emerging pathogens. In this blog, we profile the Top 10 Companies in the Point of Care Infectious Disease Testing Market—a blend of global diagnostics giants, biotech innovators, and specialized firms shaping the future of on-site infectious disease detection.
🔟 1. Trinity Biotech
Headquarters: Bray, Wicklow, Ireland
Key Offering: HIV POC Tests, Syphilis Rapid Tests, and Lateral Flow Assays
Trinity Biotech stands out as a key player in the POC infectious disease testing arena, particularly with its portfolio of rapid diagnostic tests for HIV and other sexually transmitted infections. The company’s products are designed for use in resource-limited settings, providing quick results without the need for complex laboratory equipment. This approach has made their tests invaluable in global health initiatives aimed at controlling epidemics, serving clinics and field workers in developing regions where timely diagnosis can mean the difference between life and death.
Key Innovations:
-
Development of user-friendly, one-step HIV tests approved by WHO
-
Expansion into multiplex assays for multiple infectious markers
-
Partnerships with NGOs to distribute tests in high-burden areas
Download FREE Sample Report: Point of Care Infectious Disease Testing Market – View in Detailed Research Report
9️⃣ 2. Chembio Diagnostics
Headquarters: Medford, New York, USA
Key Offering: DPP HIV Rapid Test, Dengue and Zika POC Assays
Chembio Diagnostics excels in delivering dual-path platform (DPP) technology that combines immunoassay and molecular elements for superior sensitivity in POC settings. Their tests for HIV, syphilis, and tropical diseases like dengue are widely used in emergency response scenarios. By focusing on portable devices that yield results in under 20 minutes, Chembio is helping bridge gaps in diagnostic access, especially during outbreaks where speed is critical for containment and treatment initiation.
Key Innovations:
-
Integration of microfluidics for faster, more accurate results
-
Collaborations with governments for outbreak preparedness kits
8️⃣ 3. Cardinal Health
Headquarters: Dublin, Ohio, USA
Key Offering: POC Influenza Tests, Respiratory Infection Panels, Supply Chain Solutions
Cardinal Health, a major distributor and developer in healthcare, supports POC infectious disease testing through its comprehensive range of rapid respiratory panels and logistics expertise. Their offerings include tests for influenza and RSV that integrate seamlessly into hospital workflows. With a strong emphasis on supply chain reliability, they ensure that testing kits reach frontline providers even in high-demand situations, contributing to efficient disease management worldwide.
Key Innovations:
-
Streamlined distribution networks for rapid deployment of POC kits
-
Development of bundled solutions for multi-pathogen detection
7️⃣ 4. Quest Diagnostics
Headquarters: Secaucus, New Jersey, USA
Key Offering: COVID-19 POC Tests, HIV and HPV Molecular Assays
Quest Diagnostics is a powerhouse in laboratory and POC diagnostics, extending its reach into near-patient testing for infectious diseases. Their molecular POC platforms for HPV and HIV detection offer high specificity, reducing false positives in clinical environments. As healthcare moves toward integrated care models, Quest’s ability to combine POC with lab confirmation positions them as a vital partner for physicians seeking reliable, actionable results at the point of care.
Key Innovations:
-
Goal of 50% POC integration in primary care by 2030
-
U.S.-based manufacturing of rapid test cartridges for scalability
Download FREE Sample Report: Point of Care Infectious Disease Testing Market – View in Detailed Research Report
6️⃣ 5. Bio-Rad Laboratories
Headquarters: Hercules, California, USA
Key Offering: HIV POC Combo Tests, Pneumonia Antigen Detection Kits
Bio-Rad Laboratories brings decades of experience in life sciences to the POC market, with assays that detect antigens for pneumonia and HIV simultaneously. Their portable systems are engineered for ease of use by non-specialists, making them ideal for clinics and home care. By investing in quality control mechanisms, Bio-Rad ensures consistent performance, which is essential for building trust in POC diagnostics among healthcare providers globally.
Key Innovations:
-
Proprietary quality assurance for field-deployable tests
-
Targets to expand into 100+ countries by 2026
5️⃣ 6. bioMérieux
Headquarters: Marcy-l’Étoile, France
Key Offering: BioFire Respiratory Panel, Sepsis POC Tests
bioMérieux leads with its FilmArray system, a multiplex POC platform that identifies over 20 respiratory pathogens in about an hour. This innovation has transformed infectious disease management in hospitals by enabling targeted antibiotic use, reducing unnecessary treatments. Their focus on syndromic testing addresses the complexities of co-infections, providing comprehensive insights that guide therapy decisions in real-time.
Key Innovations:
-
Current output: Thousands of panels daily for global distribution
-
Expansion plans for AI-enhanced result interpretation
4️⃣ 7. BD (Becton Dickinson)
Headquarters: Franklin Lakes, New Jersey, USA
Key Offering: Veritor Influenza Tests, HIV Rapid Assays
BD is renowned for its integrated diagnostic solutions, including digital immunoassay readers for POC infectious disease testing. Their Veritor system for influenza and strep provides digital readouts, minimizing user error. With a robust presence in both developed and emerging markets, BD supports public health programs by supplying reliable, scalable testing options that align with WHO standards.
Key Innovations:
-
Digital integration for remote result sharing
-
R&D into next-gen cartridge-based POC devices
3️⃣ 8. Siemens Healthineers
Headquarters: Erlangen, Germany
Key Offering: Atellica VTLi Influenza Test, RSV POC Assays
Siemens Healthineers dominates with automated POC systems like the Atellica platform, which delivers results for respiratory infections in minutes. Their technology emphasizes workflow efficiency in high-volume settings such as emergency departments. By leveraging advanced optics and microfluidics, Siemens is pushing the boundaries of POC accuracy, making it a go-to for hospitals combating seasonal and pandemic threats.
Key Innovations:
-
Indigenous development of cartridge-free systems
-
Collaborations with health authorities for pandemic response
2️⃣ 9. Thermo Fisher Scientific
Headquarters: Waltham, Massachusetts, USA
Key Offering: Cepheid GeneXpert HPV Tests, TB POC Molecular Diagnostics
Thermo Fisher Scientific, through its Cepheid division, offers the GeneXpert system—a cartridge-based molecular POC platform for TB, HPV, and HIV. This system’s near-lab accuracy in a portable format has revolutionized TB detection in high-burden countries. Their commitment to scalability ensures widespread adoption, supporting global efforts to eradicate infectious diseases through precise, on-demand testing.
Key Innovations:
-
Aims for 1 million cartridges produced annually
-
Major expansion in multiplex pathogen panels
1️⃣ 10. F. Hoffmann-La Roche
Headquarters: Basel, Switzerland
Key Offering: cobas Liat Influenza A/B, HIV and HBV POC Systems
F. Hoffmann-La Roche tops the list with its cobas Liat analyzer, providing molecular results for influenza, RSV, and HIV at the POC in under 20 minutes. This platform’s CLIA-waived status enables use in physician offices and pharmacies. Roche’s global reach and R&D prowess make it a leader in integrating POC testing with digital health records, enhancing patient outcomes across diverse healthcare landscapes.
Key Innovations:
-
End-to-end digital solutions for POC data management
-
Strategic alliances with telehealth providers for remote access
Read Full Report: Point of Care Infectious Disease Testing Market – View in Detailed Research Report
🌍 Outlook: The Future of Point of Care Infectious Disease Testing Is Faster and More Accessible
The point of care infectious disease testing market is experiencing a profound evolution. While traditional lab-based methods remain foundational, the sector is pouring resources into portable molecular diagnostics, AI-driven analytics, and home-use devices to democratize access. This shift not only accelerates diagnosis but also empowers early intervention, potentially saving millions of lives amid rising global mobility and climate-driven outbreaks.
📈 Key Trends Shaping the Market:
-
Explosion of molecular POC adoption in North America and Europe
-
Regulatory incentives for self-testing kits by 2030
-
Integration of AI for predictive outbreak modeling
-
Public-private partnerships for equitable distribution in low-income regions
Market Trends Affecting Point of Care Infectious Disease Testing
-
Shift to Molecular and Multiplex Testing — Companies are prioritizing nucleic acid amplification technologies over traditional immunoassays for higher sensitivity, especially for low-viral-load detections in HIV and HBV. This trend is simplifying complex diagnostics while maintaining lab-grade precision in field settings.
-
Expansion of Home and Self-Testing Options — With launches like over-the-counter COVID and HIV kits, manufacturers are addressing accessibility in remote areas, reducing the burden on healthcare systems and enabling proactive monitoring for chronic infections.
-
AI and Connectivity Integration — Cloud-connected POC devices from leaders like Roche and Thermo Fisher allow real-time data sharing with electronic health records, enhancing surveillance and personalized treatment plans for respiratory viruses like influenza and RSV.
-
Focus on Emerging Pathogens and Pandemics — Post-COVID, there’s accelerated R&D into flexible platforms for rapid adaptation to new threats, such as streptococcus-associated pneumonia, with flexible cartridge systems gaining traction in clinics and hospitals.
-
Sustainable and Cost-Effective Manufacturing — Efforts to lower production costs through scalable biotech processes are making POC tests viable for emerging markets, where affordability drives adoption for HPV and tuberculosis screening.
Read Full Report: Point of Care Infectious Disease Testing Market – View in Detailed Research Report
The companies listed above are not only detecting infectious diseases swiftly—they’re spearheading the decentralized diagnostics revolution, making healthcare more responsive and inclusive worldwide. As innovations continue to emerge, these leaders will play a pivotal role in preventing and controlling future epidemics, ensuring that rapid testing becomes a cornerstone of global health security.